[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651921":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":127,"collaborators":25,"id":129,"slug":130,"hasResults":131,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":25,"eligibilityCriteria":135,"healthyVolunteers":131,"sex":136,"minAge":137,"maxAge":25,"enrollmentInfo":138,"targetDuration":25,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","ddCMF x 4 Cycles followed by either 4 doses of dd paclitaxel given every 2 weeks or 12 doses of paclitaxel given weekly, per investigator discretion, in the adjuvant or neoadjuvant setting",[13,14],"Drug: CMF Regimen","Drug: Paclitaxel",{"label":16,"type":10,"description":17,"interventionNames":18},"Cohort 2","ddCMF x 4 Cycles in the neoadjuvant setting, in participants who have received at least 1 dose of carboplatin\u002Fpaclitaxel +\u002F- pembrolizumab",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","CMF Regimen","CMF regimen: Cyclophosphamide, Methotrexate, and Fluorouracil",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Paclitaxel","Paclitaxel will be administered as an IV infusion into a peripheral or central vein.",[9],[31],{"name":32,"affiliation":5,"role":33},"Pamela Drullinsky, MD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","516-559-1521","drullinp@MSKCC.ORG",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Koshy Alexander, MD, MBA","646-888-3659","alexandk@mskcc.org",[44,60,71,82,94,105,116],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","07920","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-74.54932,40.70621,{"lat":56,"lon":55},[59],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":25},{"facility":61,"status":46,"city":62,"state":48,"zip":63,"country":50,"countryCode":51,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)","Middletown","07748",{"type":53,"coordinates":65},[66,67],-74.11709,40.39428,{"lat":67,"lon":66},[70],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":25},{"facility":72,"status":46,"city":73,"state":48,"zip":74,"country":50,"countryCode":51,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Memorial Sloan Kettering at Bergen (Limited Protocol Activities)","Montvale","07645",{"type":53,"coordinates":76},[77,78],-74.02292,41.04676,{"lat":78,"lon":77},[81],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":25},{"facility":83,"status":46,"city":84,"state":85,"zip":86,"country":50,"countryCode":51,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)","Commack","New York","11725",{"type":53,"coordinates":88},[89,90],-73.29289,40.84288,{"lat":90,"lon":89},[93],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":25},{"facility":95,"status":46,"city":96,"state":85,"zip":97,"country":50,"countryCode":51,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Memorial Sloan Kettering at Westchester (Limited Protocol Activities)","Harrison","10604",{"type":53,"coordinates":99},[100,101],-73.71263,40.96899,{"lat":101,"lon":100},[104],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":25},{"facility":106,"status":46,"city":85,"state":85,"zip":107,"country":50,"countryCode":51,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Memorial Sloan-Kettering Cancer Center (All Protocol Activities)","10065",{"type":53,"coordinates":109},[110,111],-74.00597,40.71427,{"lat":111,"lon":110},[114],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":115},"drullinp@mskcc.org",{"facility":117,"status":46,"city":118,"state":85,"zip":119,"country":50,"countryCode":51,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Memorial Sloan Kettering at Nassau (Limited Protocol Activities)","Uniondale","11553",{"type":53,"coordinates":121},[122,123],-73.59291,40.70038,{"lat":123,"lon":122},[126],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":25},{"type":128,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100651921","phase-2-a-study-of-cyclophosphamide-methotrexate-fluorouracil-cmf-for-people-with-breast-cancer-100651921",false,"NCT07768436","A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer","STUDY OF DOSE DENSE CMF (Cyclophosphamide, Methotrexate, Fluorouracil) as an Alternative to AC (Doxorubicin, Cyclophosphamide) in 2 Regimens in EARLY STAGE BREAST CANCER for Patients Greater or Equal to 70","Inclusion Criteria:\n\n* Patients must have histologically confirmed adenocarcinoma of the breast confirmed at MSK. The patient must have had diagnostic biopsy or completion of primary surgical management, within 3 months of enrollment. Results of HER-2\u002Fneu, estrogen receptor, and progesterone receptor are required for study entry.\n* Patients must be ≥ 70 years of age.\n* Patients must have ECOG performance status \\>2 (Karnofsky score of ≥ 60%).\n* Patients may have received hormonal therapy for the purpose of chemoprevention.\n* Adjuvant\u002Fneoadjuvant chemotherapy decision to treat based on the discretion of investigator\n* Cohort 1 only: Patients have any histology except Her 2 Neu positive in the adjuvant or neoadjuvant setting\n* Cohort 2 only: Patients have triple negative (ER- (10%) PR-Her 2 Neu -) in the neoadjuvant setting\n* Cohort 2 only: Patients have received at least 1 dose of carboplatin\u002Fpaclitaxel +\u002F- pembrolizumab in the neoadjuvant setting\n\nRequired Organ Function\n\nAdequate hematologic function defined as follows:\n\n* Absolute neutrophil count (ANC) ≥ 1,500 cells\u002Fmm3\n* Platelets ≥ 100,000 cells\u002Fmm3\n\nAdequate renal function defined as follows:\n\n° Creatinine clearance (CrCL) of \\>30 mL\u002Fmin by the Cockcroft-Gault formula:\n\nCrCl (mL\u002Fmin) = \\[(\\[140 - age(years)\\] x weight (kg))\u002F72 x creatinine (mg\u002FdL)\\] (x 0.85 for female patients)\n\nAdequate hepatic function defined as follows:\n\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)\n* AST and ALT ≤3 x institutional ULN\n\n  * Patients or their Legally Authorized Representative must give written, informed consent indicating their understanding and willingness to participate in the study.\n\nExclusion Criteria:\n\n* Stage IV breast cancer\n* CARG score- high Frail 4 or more as assessed by CAIT\n* Her 2 Neu positive 3+\u002Famplified breast cancer\n* No prior chemotherapy within 1 year of study enrollment\n* Cohort 2 only: patients may not receive pembrolizumab during dd CMF treatment","ALL","70 Years",{"count":139,"type":140},76,"ESTIMATED","INTERVENTIONAL",[143],"PHASE2","The purpose of this study is to find out if it is practical (feasible) to give dose-dense CMF (cyclophosphamide, methotrexate, and fluorouracil) in two standard chemotherapy regimens in people with breast cancer, age 70 and older.",[146,147,148],"Adenocarcinoma of the Breast","Breast Cancer","Triple Negative Breast Cancer",[150,151,152,5,153],"adenocarcinoma of the breast","breast cancer","triple negative breast cancer","26-303","2026-08-12",{"date":156,"type":157},"2026-08-17","ACTUAL",{"date":159,"type":157},"2026-08-11",{"date":161,"type":140},"2030-08-11",{"name":5,"class":6},7]